In the post-acute phase, we report increased risks and 12-month burdens of incident diabetes and antihyperglycaemic use in people with COVID-19 compared with a contemporary control group of people who were enrolled during the same period and had not contracted SARS-CoV-2, and a historical control group from a pre-pandemic era.

Post-acute COVID-19 care should involve identification and management of diabetes.

In the post-acute phase of the disease, compared with the contemporary control group, people with COVID-19 exhibited an increased risk and excess burden of incident diabetes; and an increased risk and excess burden of incident antihyperglycaemic use.

Additionally, analyses to estimate the risk of a composite endpoint of incident diabetes or antihyperglycaemic use yielded a HR of 1·46 and an excess burden of 18·03 per 1000 people at 12 months.

Read More